Quarterly results
2018 Second Quarter and R&D update
We announced our second quarter 2018 results on Wednesday 25 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our performance and financial outlook, and Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update.
Highlights
Downloads
- Q2 2018 results and R&D update announcement PDF - 1.0MB
- Q2 2018 slides - Emma Walmsley PDF - 495.7KB
- Q2 2018 slides - Simon Dingemans PDF - 131.7KB
- R&D update slides - Hal Barron PDF - 1.9MB
- Q2 2018 results transcript - Part 1 PDF - 188.4KB
- Q2 2018 results transcript - Part 2 PDF - 242.3KB
- Q2 2018 results infographic PDF - 556.7KB
- Q2 2018 US dollar translation PDF - 131.6KB
- Q2 2018 pre announcement aide memoire PDF - 742.2KB
-
2011 First Quarter - released 27 April 2011
Andrew Witty, CEO, discusses our first quarter results 2011.
Key highlights
- Reported sales -10%, underlying sales +4%
- EPS before major restructuring 32.2p (+9%), dividend 16p (+7%)
-
2010 Fourth Quarter - released 03 February 2011
Andrew Witty, CEO, discusses our fourth quarter results 2010.
Key highlights
- Long-term share buy-back programme initiated
- 2010 dividend up 7% to 65p
-
2010 Third Quarter - released 21 October 2010
Andrew Witty, CEO, discusses our third quarter results 2010
Key highlights
- Q3 EPS before major restructuring of 28.2p
- Q3 dividend up 7% to 16p
-
2010 Second Quarter - released 21 July 2010
Andrew Witty, CEO, discusses our second quarter results 2010.
Key highlights
- Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge)
- Q2 dividend increased 7% to 15p
Other key information
-
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
-
Press releases
Keep up to date with our news and recent announcements
-
Product pipeline
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III
